title: Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.
abstract: OBJECTIVE
  Inhibitors of the mammalian target of rapamycin (mTOR) kinase have shown clinical activity in several lymphoma subtypes. Sirolimus, an mTOR inhibitor, also has activity in the treatment and prophylaxis of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem-cell transplantation (HSCT). We hypothesized that the use of sirolimus for GVHD prophylaxis in patients with lymphoma might lead to improved survival after transplantation through a decreased incidence of disease progression.
  
  
  METHODS
  We retrospectively analyzed 190 patients who underwent transplantation for lymphoma. We compared the outcomes of patients who received sirolimus for GVHD prophylaxis with those of patients who received transplantation with a combination of a calcineurin inhibitor and methotrexate without sirolimus.
  
  
  RESULTS
  Overall survival (OS) after transplantation was significantly superior in the sirolimus group, which was confirmed in multivariable analysis. The benefit was restricted to patients undergoing reduced-intensity conditioning (RIC) HSCT (3-year OS, 66% for sirolimus group v 38% for no-sirolimus group; P = .007; hazard ratio [HR] for mortality in multivariable analysis = 0.5, P = .042). Patients who received sirolimus had a similar incidence of nonrelapse mortality but a decreased incidence of disease progression compared with patients who did not receive sirolimus (3-year cumulative incidence of progression, 42% v 74%, respectively; P < .001; HR for progression in multivariable analysis = 0.4, P = .01). The effect of sirolimus persisted after adjusting for the occurrence of GVHD. No such survival advantage was apparent in a similar comparison of patients who underwent transplantation for diseases other than lymphoma.
  
  
  CONCLUSIONS
  This study suggests that sirolimus can independently decrease the risk of lymphoma progression after RIC HSCT, paving the way for prospective clinical trials.
authors.affiliation: Departments of Medical Oncology and Biostatistics, Dana-Farber Cancer Institute, Boston 02115, USA. parmand@partners.org
authors.forename: Philippe
authors.initials: P
authors.lastname: Armand
authors.forename: Supriya
authors.initials: S
authors.lastname: Gannamaneni
authors.forename: Haesook T
authors.initials: HT
authors.lastname: Kim
authors.forename: Corey S
authors.initials: CS
authors.lastname: Cutler
authors.forename: Vincent T
authors.initials: VT
authors.lastname: Ho
authors.forename: John
authors.initials: J
authors.lastname: Koreth
authors.forename: Edwin P
authors.initials: EP
authors.lastname: Alyea
authors.forename: Ann S
authors.initials: AS
authors.lastname: LaCasce
authors.forename: Eric D
authors.initials: ED
authors.lastname: Jacobsen
authors.forename: David C
authors.initials: DC
authors.lastname: Fisher
authors.forename: Jennifer R
authors.initials: JR
authors.lastname: Brown
authors.forename: George P
authors.initials: GP
authors.lastname: Canellos
authors.forename: Arnold S
authors.initials: AS
authors.lastname: Freedman
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Soiffer
authors.forename: Joseph H
authors.initials: JH
authors.lastname: Antin
mesh_terms: D000328:Adult; D000368:Aged; D001900:Boston; D019703:Calcineurin / Q000378:metabolism; D065095:Calcineurin Inhibitors; D018572:Disease-Free Survival; D006086:Graft vs Host Disease / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D008223:Lymphoma / Q000401:mortality / Q000601:surgery*; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D012189:Retrospective Studies; D020123:Sirolimus / Q000627:therapeutic use*; D013997:Time Factors; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D019703:Calcineurin; D020123:Sirolimus; D008727:Methotrexate